Dr. Jonathan E. Rosenberg, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 106
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Harvard Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 212436 · CA license A71732 · MA license 235529 -
Internal Medicine Physician
CA license A71732 · MA license 235529
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Memorial Solid Tumor Group (234 clinicians)
- Msk Harrison (132 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 106
- Services billed
- 860
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 367 | 67 |
| Established patient office or other outpatient visit, 30-39 minutes | 161 | 54 |
| New patient office or other outpatient visit, 60-74 minutes | 32 | 32 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in New York, NY | 33 |
| Tamsulosin Hcl Other prescribers in New York, NY | 16 |
| Triamcinolone Acetonide Other prescribers in New York, NY | 15 |
| Metformin Hcl Er (metformin hcl) Other prescribers in New York, NY | 14 |
| Dexamethasone Other prescribers in New York, NY | 13 |
| Omeprazole Other prescribers in New York, NY | 13 |
| Levothyroxine Sodium Other prescribers in New York, NY | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 23 payments worth $14,809 in total to this clinician.
| Pfizer Inc. | $7,535 |
|---|---|
| AstraZeneca UK Limited | $4,982 |
| Samsung Bioepis Co., LTD. | $1,110 |
| AstraZeneca Pharmaceuticals LP | $964 |
| La Jolla Pharmaceutical Company | $128 |
| Gilead Sciences, Inc. | $47.00 |
| Janssen Biotech, Inc. | $43.10 |
| Consulting Fee | $13,597 |
|---|---|
| Food and Beverage | $1,155 |
| Compensation for services other than consulting (speaking, faculty) | $56.90 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca UK Limited Dec 15, 2025 | Consulting Fee IMFINZI · Oncology | $3,280 |
| Pfizer Inc. Nov 20, 2025 | Consulting Fee | $1,875 |
| Pfizer Inc. Nov 28, 2025 | Consulting Fee PADCEV · ONCOLOGY | $1,875 |
| Pfizer Inc. Jun 16, 2025 | Consulting Fee | $1,875 |
| AstraZeneca UK Limited Oct 22, 2025 | Consulting Fee IMFINZI · Oncology | $1,640 |
| Samsung Bioepis Co., LTD. Jul 24, 2025 | Consulting Fee E303 · Medical Oncology | $1,040 |
| AstraZeneca Pharmaceuticals LP Nov 13, 2025 | Consulting Fee IMJUDO · Oncology | $927 |
| Pfizer Inc. Nov 26, 2025 | Consulting Fee | $625 |
| Pfizer Inc. Sep 5, 2025 | Consulting Fee | $460 |
| Pfizer Inc. Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) | $56.90 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $480,065 in research payments for these studies, mostly to the institutions running them.
- A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly and Company · Active, not recruiting · NCT06238479 - A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIB…
Merck Sharp & Dohme LLC - A study of enfortumab vedotin ASG22CE as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.